| 21.4853 0.005 (0.02%) | 04-21 13:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 25.1 |
1-year : | 29.32 |
| Resists | First : | 21.49 |
Second : | 25.1 |
| Pivot price | 21.46 |
|||
| Supports | First : | 21.36 |
Second : | 21.28 |
| MAs | MA(5) : | 21.47 |
MA(20) : | 21.44 |
| MA(100) : | 13.82 |
MA(250) : | 9.81 |
|
| MACD | MACD : | 0.8  |
Signal : | 1.1 |
| %K %D | K(14,3) : | 85.3 |
D(3) : | 80.3 |
| RSI | RSI(14): 79.7 |
|||
| 52-week | High : | 21.49 | Low : | 5.63 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DAWN ] has closed below upper band by 20.8%. Bollinger Bands are 98.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 21.52 - 21.6 | 21.6 - 21.69 |
| Low: | 21.26 - 21.36 | 21.36 - 21.45 |
| Close: | 21.32 - 21.48 | 21.48 - 21.62 |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Tue, 21 Apr 2026
Day One Biopharmaceuticals stock hits 52-week high at 21.5 USD - Investing.com
Mon, 20 Apr 2026
(DAWN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Fri, 17 Apr 2026
DAWN Stock Price, Quote & Chart | DAY ONE BIOPHARMACEUTICALS I (NASDAQ:DAWN) - ChartMill
Tue, 14 Apr 2026
[SC TO-T/A] Day One Biopharmaceuticals, Inc. Amended Third-Party Tender Offer | DAWN SEC Filing - Form SC TO-T/A - Stock Titan
Mon, 13 Apr 2026
Access Industries group tenders Day One (DAWN) 12.9M-share stake at $21.50 - Stock Titan
Sat, 07 Mar 2026
Day One (DAWN) Soars 100% on $2.5-Billion Merger - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 103 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 16.8 (%) |
| Held by Institutions | 85.4 (%) |
| Shares Short | 7,240 (K) |
| Shares Short P.Month | 10,150 (K) |
| EPS | -1.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.28 |
| Profit Margin | -67.9 % |
| Operating Margin | -51.2 % |
| Return on Assets (ttm) | -14.7 % |
| Return on Equity (ttm) | -22.8 % |
| Qtrly Rev. Growth | 83.9 % |
| Gross Profit (p.s.) | 1.36 |
| Sales Per Share | 1.53 |
| EBITDA (p.s.) | -1.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -104 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -20.66 |
| PEG Ratio | 0 |
| Price to Book value | 5.01 |
| Price to Sales | 14.02 |
| Price to Cash Flow | -21.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|